PMID- 33462371
OWN - NLM
STAT- MEDLINE
DCOM- 20210930
LR  - 20230127
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Jan 18
TI  - Calcium-based phosphate binder use is associated with lower risk of osteoporosis 
      in hemodialysis patients.
PG  - 1648
LID - 10.1038/s41598-021-81287-4 [doi]
LID - 1648
AB  - Loss of bone mineral density (BMD) is a substantial risk of mortality in addition 
      to fracture in hemodialysis patients. However, the factors affecting BMD are not 
      fully determined. We conducted a single-center, cross-sectional study on 321 
      maintenance hemodialysis patients who underwent evaluation of femoral neck BMD 
      using dual-energy X-ray absorptiometry from August 1, 2018, to July 31, 2019. We 
      examined factors associated with osteoporosis defined by T-score of </=  - 2.5, 
      using logistic regression models. Median age of patients was 66 years, and 131 
      patients (41%) were diagnosed with osteoporosis. Older age, female, lower body 
      mass index, diabetes mellitus, and higher Kt/V ratios were associated with higher 
      osteoporosis risk. The only medication associated with lower osteoporosis risk 
      was calcium-based phosphate binders (CBPBs) [odds ratio (OR), 0.41; 95% 
      confidence interval (CI), 0.21-0.81]. In particular, CBPB reduced the 
      osteoporosis risk within subgroups with dialysis vintage of >/= 10 years, albumin 
      level of < 3.5 mg/dL, active vitamin D analog use, and no proton pump inhibitor 
      (PPI) use. In conclusion, CBPB use was associated with lower osteoporosis risk in 
      hemodialysis patients. This effect might be partially attributable to calcium 
      supplementation, given its higher impact in users of active vitamin D analogs or 
      non-users of PPI, which modulate calcium absorption.
FAU - Hashimoto, Hiroko
AU  - Hashimoto H
AD  - Department of Nephrology, Shuuwa General Hospital, 1200 Yaharashinden, Kasukabe, 
      Saitama, 344-0035, Japan.
FAU - Shikuma, Satomi
AU  - Shikuma S
AD  - Department of Nephrology, Shuuwa General Hospital, 1200 Yaharashinden, Kasukabe, 
      Saitama, 344-0035, Japan.
FAU - Mandai, Shintaro
AU  - Mandai S
AD  - Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo 
      Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo, 113-8519, Japan. 
      smandai.kid@tmd.ac.jp.
FAU - Adachi, Susumu
AU  - Adachi S
AD  - Department of Cardiology, Shuuwa General Hospital, 1200 Yaharashinden, Kasukabe, 
      Saitama, 344-0035, Japan.
FAU - Uchida, Shinichi
AU  - Uchida S
AD  - Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo 
      Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo, 113-8519, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210118
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Calcium-Regulating Hormones and Agents)
RN  - 0 (Phosphates)
RN  - 1406-16-2 (Vitamin D)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aged
MH  - Bone Density/*drug effects
MH  - Calcium/*therapeutic use
MH  - Calcium-Regulating Hormones and Agents/therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoporosis/etiology/pathology/*prevention & control
MH  - Phosphates/*therapeutic use
MH  - Renal Dialysis/adverse effects/instrumentation/*methods
MH  - Risk Factors
MH  - Vitamin D/*therapeutic use
PMC - PMC7814124
COIS- The authors declare no competing interests.
EDAT- 2021/01/20 06:00
MHDA- 2021/10/01 06:00
PMCR- 2021/01/18
CRDT- 2021/01/19 05:54
PHST- 2020/07/10 00:00 [received]
PHST- 2021/01/04 00:00 [accepted]
PHST- 2021/01/19 05:54 [entrez]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/10/01 06:00 [medline]
PHST- 2021/01/18 00:00 [pmc-release]
AID - 10.1038/s41598-021-81287-4 [pii]
AID - 81287 [pii]
AID - 10.1038/s41598-021-81287-4 [doi]
PST - epublish
SO  - Sci Rep. 2021 Jan 18;11(1):1648. doi: 10.1038/s41598-021-81287-4.